Novartis’ Lucentis Approved In Japan For Choroidal Neovascularization And Macular Edema
This article was originally published in PharmAsia News
MHLW approved additional indications of choroidal neovascularization in pathological myopia and macular edema associated with retinal vein occlusion for Novartis Japan’s Lucentis intravitreal injection (ranibizumab).
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.